Medinet gets exclusive rights to Histogenics' NeoCart in Japan

08 Oct 2021

Histogenics Corp. licensed Medinet Co. Ltd. exclusive rights to develop and commercialize NeoCart in Japan.

Medical Devices
Pharmaceuticals
Medical Devices
- Biomaterials
- Implantable Devices
Biotechnology
- Gene Therapy, Cell Therapy
- Drug Discovery Tools
  - Bioinformatics

Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)

Already a Biomedtracker subscriber? You have access to the full deal record through your subscription

Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products.

Questions?

Please contact Sales at: (212) 520-2765 or email [email protected]

Related Companies

Medinet gets exclusive rights to Histogenics' NeoCart in Japan

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

DCD.EmailPopout.Notice